Amgen Inc.
Bear Case (25th pct.)
-48.7% vs price
Base Case (Median)
-16.2% vs price
Bull Case (75th pct.)
-15.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-906.04 | -340.8% | High (40%) |
| PE Comparable | $319.93 | -15.0% | Medium (25%) |
| Growth Trajectory DCF | $407.53 | 8.3% | Medium (20%) |
| Graham Number | $72.13 | -80.8% | Medium (40%) |
| EV/EBITDA | $314.09 | -16.5% | Medium (20%) |
| EV/FCF | $319.59 | -15.1% | Medium (20%) |
| Earnings Power Value | $315.26 | -16.2% | Medium (50%) |
Based on 7 out of 8 methods, AMGN appears overvalued at the current price of $376.26. The base case fair value of $315.26 implies 16.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.